neutralizing monoclonal antibodies – Page 5 – Communicable Diseases Research

Neutralizing antibodies for the prevention and treatment of COVID-19

코로나19 예방 및 치료를 위한 중화항체

Review

Published on 2021-09-082022-09-11
Journal: Cellular and Molecular Immunology [Category] SARS, 변종, 비임상, 신약개발, 임상, 진단,

Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19

사설: COVID-19 고위험군 개인을 위한 SARS-CoV-2에 대한 노출 후 예방 중화 단일클론 항체

Editorial

Published on 2021-08-162022-09-11
Journal: Medical science monitor : international medical jo [Category] SARS, 변종, 진단,

[키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approval approvals approved authorization bamlanivimab Casirivimab children clinical development Clinical studies clinical study coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 progression diagnostic drug editorial Effectiveness Emergency Emergency use Emergency use authorization etesevimab EUA exposure to FDA food high risk Imdevimab individual initial Mild mild to moderate Moderate COVID-19 monoclonal antibody monotherapy Neutralizing neutralizing monoclonal antibodies neutralizing monoclonal antibody Older pandemic Preclinical Prevent progression Prophylactic REGEN-COV Regulatory Regulatory Authorities respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 therapeutic therapy treat US Food and Drug Administration Vaccine variants of SARS-CoV-2
[DOI] 10.12659/MSM.934393 PMC 바로가기 [Article Type] Editorial

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

SARS-CoV-2에 대한 강력한 인간 중화 항체의 식별이 치료제 및 예방 개발에 미치는 영향

Article

Published on 2021-08-092022-09-10
Journal: Nature Communications [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단, 치료기술, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus addition Administered Analysis angiotensin anti-SARS-CoV-2 Anti-viral treatment antibodies antibody Applying Candidates coronavirus detectable determinate Diseases domain drug Economy effective drug effective drugs Emerging infectious diseases epitope Epitopes Fab germline global public health hACE2 high affinity human Angiotensin-converting enzyme identification identify Impact implication infected patient infected patients Infectious diseases Lung injury maturation mechanism mice monoclonal antibodies monoclonal antibody naïve neutralize Neutralizing Neutralizing antibodies neutralizing antibody neutralizing monoclonal antibodies neutralizing monoclonal antibody Novel coronavirus platform Prophylactic prophylactically RBD reduce respiratory reveal SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spike protein the RBD the SARS-CoV-2 therapeutic Vaccines Viral viral infection viral titer
[DOI] 10.1038/s41467-021-25153-x PMC 바로가기 [Article Type] Article

Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19

COVID-19에 걸린 회복기 환자에서 유도된 항체에 의한 중화에 대한 SARS-CoV-2 변이체의 내성

Article

Published on 2021-07-132022-09-11
Journal: Cell Reports [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike anti-spike antibody anti-spike MAbs antibody antibody-based therapies antibody-based therapy B.1.1.7 B.1.351 Brazil caused Cluster convalescent COVID-19 patient convalescent patient Convalescent patients convalescent plasma convalescent plasma samples coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 effective Efficacy evaluate FIVE high affinity IgG Immunoglobulin Impact Infection mAb mAbs memory B cells Mutation neutralization Neutralizing neutralizing activities Neutralizing antibodies neutralizing antibody neutralizing monoclonal antibodies neutralizing monoclonal antibody P.1 patients Rapid Receptor-binding domain resistance respiratory robust SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly single-cell South Africa Spike protein Spread the receptor-binding domain the spike protein therapeutic option Vaccine variant variants with COVID-19
[DOI] 10.1016/j.celrep.2021.109385 PMC 바로가기 [Article Type] Article

Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques

2개의 강력한 중화 항체 조합을 통한 조기 치료는 SARS-CoV-2에 감염된 원숭이에서 임상 결과를 개선하고 바이러스 복제 및 폐 염증을 감소시킵니다.

Research Article

Published on 2021-07-062022-09-10
Journal: PLoS Pathogens [Category] SARS, 변종, 진단,

[키워드] 24 hour 24 hours animal animals anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibodies antibody antibody combination clinic clinical development Clinical outcome Clinical signs Clinical studies clinical testing Combination combinations controls COVID-19 COVID-19 disease develop dose early infection effective extension group half-lives High dose high risk histology Human IMPROVE infected individual Infection inoculated interstitial pneumonia intra-tracheally intranasally intravenously investigated less Lower respiratory tract lung Lung inflammation macaque maintain monoclonal antibodies monoclonal antibody mutations neutralize neutralizing antibody neutralizing monoclonal antibodies Placebo progression promise Prophylactic provide reduce reduced respiratory respiratory tract rhesus rhesus macaque SARS-CoV-2 SARS-COV-2 infection severe COVID-19 disease shown significantly Support tested therapeutic efficacy therapeutic intervention Therapeutic strategies three groups treated Treatment upper and lower respiratory tract variant Viral Viral variants virus replication
[DOI] 10.1371/journal.ppat.1009688 PMC 바로가기 [Article Type] Research Article

Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant

SARS-CoV-2 스파이크에서 우성 및 하위 우성 에피토프를 인식하는 단일클론 항체의 중화 효능은 B.1.1.7 변이체의 영향을 받습니다.

Article

Published on 2021-06-082022-09-10
Journal: Immunity [Category] MERS, SARS, 변종, 진단,

[키워드] Abstract Affect antibodies antibody antigenic antigenic drift antigenicity arising Asymptomatic B.1.1.7 B.1.1.7 variant characterized circulating SARS-CoV-2 variant circulating SARS-CoV-2 variants COVID-19 disease COVID-19 disease severity disease severity dominant Donor epitope Epitopes glycan host cell host cells Immune escape impacted individual infected individuals Infectious virus less monoclonal antibodies monoclonal antibody MOST Mutation N-terminal domain NAb NAbs neutralization neutralization activity Neutralizing activity Neutralizing antibodies neutralizing antibody neutralizing epitope neutralizing epitopes neutralizing monoclonal antibodies neutralizing monoclonal antibody NTD overlapping plasma potent RBD receptor ACE2 Receptor binding domain recognizing retained S2 subunit SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 variants SARS-CoV-2-infected individuals specific antibodies spike The B.1.1.7 the RBD the SARS-CoV-2 variant variant of concern variants Viral viral entry
[DOI] 10.1016/j.immuni.2021.03.023 PMC 바로가기 [Article Type] Article

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

SARS-CoV-2 501Y.V2 변이체는 더 높은 감염성은 없지만 면역 탈출은 있습니다

Article

Published on 2021-04-292022-09-11
Journal: Cell [Category] MERS, SARS, 변종, 진단, 치료기술,

[키워드] 501Y.V2 Abstract caused Cell cell type cell types cells convalescent convalescent patient Convalescent patients dominant E484K Efficacy escaped except for exhibit experiment hACE2 higher infectivity Immune escape immunized immunized mice increase in individuals Infectivity inhibitory effect Inhibitory effects K417N lack mACE2 mice monoclonal antibodies monoclonal antibody multiple mutation multiple mutations murine Mutation N501Y N501Y mutation neutralization neutralization ability neutralizing antibody neutralizing monoclonal antibodies neutralizing monoclonal antibody polyclonal antibodies polyclonal antibody Pseudotyped virus Pseudotyped viruses receptor binding region Receptor-binding domain reduced SARS-CoV-2 sera significantly South Africa Spike protein susceptibility the receptor-binding domain Vaccines variant variant of SARS-CoV-2 variants variants of SARS-CoV-2 Viral viral spike protein viruses
[DOI] 10.1016/j.cell.2021.02.042 PMC 바로가기 [Article Type] Article

Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein

Research Article

Published on 2021-03-192022-10-31
Journal: Heliyon [Category] COVID-19,

[키워드] ACE ACE2 Analysis antibodies antibody Belgium binding binding domain circulating clades Comparative genomics Consensus country COVID-19 D614G docking enzyme expected EY6A Fatality rate France Genome higher affinity higher fatality rate higher infectivity India infection rates Interaction isolate isolates Italy lowest Molecular dynamics simulation mortality rate Mutation N439K Neutralizing antibodies neutralizing monoclonal antibodies novel coronavirus SARS-CoV-2 pandemic Pathogenesis Prevalence prevalent RBM reactivity receptor Receptor binding domain receptor binding motif reported SARS-CoV-2 SARS-CoV-2 genome SARS-CoV-2 virus Spike protein Support USA variant virulence Wuhan-1
[DOI] 10.1016/j.heliyon.2021.e06564 PMC 바로가기 [Article Type] Research Article

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

순환하는 SARS-CoV-2 스파이크 N439K 변이체는 항체 매개 면역을 피하면서 체력을 유지합니다

Article

Published on 2021-03-042022-09-11
Journal: Cell [Category] Fulltext, SARS, 변종, 진단,

[키워드] antibody Antibody therapeutics binding affinity Clinical outcome consequence COVID-19 disease drug Efficacy Emergency use epidemiological evade FDA fitness food hACE2 hACE2 receptor highlighting Immunity immunodominant increase Infection Lineage mAb mAbs maintain molecular monoclonal antibody escape mutate Mutation N439K neutralizing monoclonal antibodies neutralizing monoclonal antibody polyclonal polyclonal antibody polyclonal sera prevalent protein structure RBM receptor binding motif receptor-binding motif reduce reducing Replication response responses S protein SARS-CoV-2 SARS-CoV-2 S SARS-CoV-2 spike spike Surveillance the SARS-CoV-2 Therapeutics US Food and Drug Administration Usage Vaccine variable region variant Viral viral fitness virulence virus viruses wild type wild-type
[DOI] 10.1016/j.cell.2021.01.037 PMC 바로가기 [Article Type] Article

Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV

SARS-CoV-2 및 SARS-CoV 모두에 대해 교차 중화 활성을 갖는 인간 단일클론 항체인 MW06의 특성화

Article

Published on 2021-01-012022-09-11
Journal: mAbs [Category] 변종, 진단,

[키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition ADE alignment angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 anti-SARS-CoV-2 antibody antibody-based therapy Antibody-dependent enhancement antibody-dependent enhancement (ADE) assays authorization B.1.1.7 B.1.351 B.1.617.1 bind caused characterization clinical trial cocktail complex conserved coronavirus coronavirus strains COVID-19 cross-neutralization activity cross-reactive demonstrated disrupt Effect effective effective interventions Emergency use epitope global pandemic Human monoclonal antibody in vitro assays Interaction Intervention mAb mAbs monoclonal antibody mutations neutralization neutralization activity neutralizing monoclonal antibodies P.1 Phase 2 Potential Prevent Prophylactic provide RBD receptors recognize respiratory SARS-CoV SARS-CoV-2 SARS-COV-2 infection SARS-related coronavirus severe acute respiratory syndrome Coronavirus spike receptor-binding domain Strains therapeutic efficacy Treatment treatment of COVID-19 variant variants variants of concern widespread
[DOI] 10.1080/19420862.2021.1953683 PMC 바로가기 [Article Type] Article